Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22506220 | 0.84 | CRBN (0.45) | CRBNDDB1RORCTDP1 | |
| SCHEMBL16887654 | 0.81 | CRBN (0.38) | CRBNDDB1RORCTDP1 | |
| SCHEMBL11902837 | 0.77 | GRM2 (0.41) | CRBNDDB1RORCTDP1 | |
| SCHEMBL1666003 | 0.77 | GRM2 (0.41) | CRBNDDB1RORCTDP1 | |
| SCHEMBL14609564 | 0.77 | PDE7A (0.50) | CRBNPDE7ATDP1 | |
| SCHEMBL7884532 | 0.77 | PDE7A (0.50) | CRBNPDE7ATDP1 | |
| SCHEMBL573347 | 0.73 | CRBN (0.38) | CRBNDDB1PDE7ATDP1 | |
| SCHEMBL15216895 | 0.73 | GAA (0.40) | CRBNPDE7ATDP1 | |
| SCHEMBL17057390 | 0.73 | GAA (0.40) | CRBNPDE7ATDP1 | |
| SCHEMBL14123665 | 0.73 | ALDH1A1 (0.37) | CRBNPDE7ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | CRBN 1606/4885DDB1 4253/4885RORC 1/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | CRBN 1895/4885DDB1 4266/4885RORC 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.